TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02733432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 Vaginal Gel (3%)
Description: CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 External gel (1%)
Description: CD101 external gel (1%) applied topically twice daily over 72 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 Vaginal Ointment (6%)
Description: CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 External ointment (1%)
Description: CD101 external ointment (1%) applied topically twice daily over 72 hours as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: oral fluconazole (150mg) on Day 1
Study: NCT02958514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intense pulsed light
Description: Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.

Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin and Dexamethasone Ophthalmic Ointment
Study: NCT03673852

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WE Harambee
Description: WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Health Home Enrollment
Description: A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
Study: NCT00905411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PacDASH intervention
Description: Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study.
Study: NCT06055101

Intervention type: DRUG
Group type: OTHER
Intervention: DEXMEDETOMIDINE
Description: DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water.

Intervention type: DRUG
Group type: OTHER
Intervention: Neostigmine
Description: Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane.
Study: NCT00212836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg by mouth once daily for 26 weeks
Study: NCT03822637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine + albuterol
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline + albuterol
Description: Normal saline is a placebo agent and Albuterol is a bronchodilator.
Study: NCT01921387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSC transplant
Study: NCT01923883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Description: EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
Study: NCT01921387

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Description: Given IV
Study: NCT00304746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00225069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of sympathectomy
Description: T2 sympathectomy or T2-T3 sympathectomy
Study: NCT03723005

Intervention type: DEVICE
Intervention: Neolight Phototherapy Mattress
Description: Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.

Intervention type: DEVICE
Intervention: Standard-of-Care
Description: Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
Study: NCT03895112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID200
Description: dose cohorts of 21-day cycles
Study: NCT01668030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzymatic agent
Description: Enzymatic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzymatic agent
Description: Enzymatic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacitracin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacitracin
Study: NCT03173586

Intervention type: OTHER
Intervention: Sugar sweetened beverage (SSB)
Description: This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
Study: NCT01103778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade®)
Description: Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
Study: NCT01102218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg qd po for 6 months
Study: NCT02483078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study: NCT01547364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of 10 ml of normal saline into the caudal epidural space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: Injection of 10 ml or dextrose 5% in water into the caudal epidural space
Study: NCT01366092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
Study: NCT04680234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMEP kit
Description: Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermapen
Description: Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
Study: NCT01618136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7449 alone
Description: Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7449 plus TMZ
Description: Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7449 plus carboplatin and paclitaxel
Description: Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
Study: NCT01923883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echoendoscope Olympus GF-UCT240

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echoendoscope Olympus GF-UCT240
Study: NCT02283294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT00771381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAZA PET scan
Description: Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluGlucoScan Injection (18F-FDB) PET scan
Description: Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
Study: NCT02158312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)
Description: 2 mA for 20 minutes transcranial direct current stimulation
Study: NCT01394952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT00584844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live F tularensis Vaccine
Description: Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
Study: NCT00700323

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PS-Omega3 conjugate supplementation
Study: NCT05086861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oesophageal pacing after left atrial posterior wall isolation
Description: Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
Study: NCT01808378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded adipose-derived stem cells
Description: Local injection of autologousadipose derived stem cells
Study: NCT02258802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
Study: NCT02465931

Intervention type: OTHER
Group type: OTHER
Intervention: Paper and Pencil Informed Consent
Description: Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
Study: NCT00700323

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00349726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol lower volume
Description: 60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol higher volume
Description: 120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Study: NCT02465931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Informed Consent Tool
Description: Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
Study: NCT01071408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroke prevention care program
Description: Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
Study: NCT02621632

Intervention type: DEVICE
Group type: OTHER
Intervention: (Socknleg)To done of a novel compression system
Description: To done a novel compression system.
Study: NCT02483078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Background Regimen
Description: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optimized Background Regimen
Description: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Study: NCT01536106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Bone marrow mononuclear cells
Description: Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Intracoronary infusion of autologous peripheral blood.
Study: NCT03067129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir Adult Formulation
Description: Co-formulated film-coated tablet (100 mg/40 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir + Pibrentasvir Pediatric Formulation
Description: Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
Study: NCT01577602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed medication list
Description: Provide a list of patient's current medication list as noted in the EMR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open ended question
Description: medical assistants begin medication reconciliation with a scripted open ended question.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: Combines the printed medication list with the open ended question
Study: NCT03423602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQseal®
Description: Large hole closure system
Study: NCT04470388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-514
Study: NCT01941602

Intervention type: DRUG
Intervention: prophylactic enoxaparin
Description: enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed

Intervention type: PROCEDURE
Intervention: non-prophylactic
Description: no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
Study: NCT03067129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir + Pibrentasvir Pediatric Formulation
Description: Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir + Pibrentasvir Pediatric Formulation
Description: Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
Study: NCT03562754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reduced systemic heparin anticoagulation
Description: receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Citrate Anticoagulation
Description: intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer